BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19953512)

  • 1. The long-term results of the "Endeavor" stent.
    Kornovski R
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):996-9. PubMed ID: 19953512
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up of the First In Man experience with everolimus-eluting stents.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):1004-5. PubMed ID: 20517960
    [No Abstract]   [Full Text] [Related]  

  • 3. Are we totally clear?
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):987-8. PubMed ID: 19953511
    [No Abstract]   [Full Text] [Related]  

  • 4. Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading?
    Hillegass WB
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):58-9. PubMed ID: 20578193
    [No Abstract]   [Full Text] [Related]  

  • 5. SES for AMI: moving in the right direction.
    Vetrovec GW
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):333-4. PubMed ID: 19642181
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence.
    Byrne RA; Kastrati A
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo.
    Belardi J
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848
    [No Abstract]   [Full Text] [Related]  

  • 9. Stenting unprotected left main: the outcome is not always favorable.
    Colombo A
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):539-40. PubMed ID: 18307235
    [No Abstract]   [Full Text] [Related]  

  • 10. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
    Park SJ
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug-eluting stent in saphenous vein graft lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):894-5. PubMed ID: 18498140
    [No Abstract]   [Full Text] [Related]  

  • 12. A generation 2.5 drug-eluting stent?
    Ellis SG
    JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. If I've heard it once, I've heard it (not yet) a hundred times.
    Butman SM
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224
    [No Abstract]   [Full Text] [Related]  

  • 15. Late stent thrombosis--the "vulnerable" stent.
    Waksman R
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):54-6. PubMed ID: 17585385
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation of patients with late target lesion revascularization.
    Kaneda H
    Catheter Cardiovasc Interv; 2008 Nov; 72(5):749. PubMed ID: 18942148
    [No Abstract]   [Full Text] [Related]  

  • 18. Off-label use and the spectre of drug-eluting stent thrombosis.
    Cook S; Wenaweser P
    Circ Cardiovasc Interv; 2009 Aug; 2(4):273-6. PubMed ID: 20031728
    [No Abstract]   [Full Text] [Related]  

  • 19. Percutaneous revascularization of the "unprotected" left main during acute myocardial infarction: "Dare to struggle! Dare to win!".
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):22-4. PubMed ID: 19089931
    [No Abstract]   [Full Text] [Related]  

  • 20. What kind of stent for you today and how would you like it prepared?
    Butman SM
    Catheter Cardiovasc Interv; 2007 Aug; 70(2):173-4. PubMed ID: 17630654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.